Shots:

• The MAA is based on the P-III TRuE-V clinical program that consists of 2 P-III studies ie., TRuE-V1 & V2 evaluating ruxolitinib cream in 600+ patients aged =12yrs. with vitiligo
• The therapy demonstrated improvements in facial & total body repigmentation @ 24wks. of treatment, patients treated with ruxolitinib cream did not report site reactions while the overall safety profile was consistent with previous study data
• With the validation, the submission is complete & the EMA will now initiate the review procedure. In Sept'21, ruxolitinib cream has received the US FDA's approval for chronic treatment of mild to moderate AD in non-immunocompromised patients aged 12yrs.

 ­to­  | Ref: Businesswire | Image: The Business Journals